Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Outcomes of a novel intrathoracic esophagogastric anastomotic technique.

Kesler KA, Ramchandani NK, Jalal SI, Stokes SM, Mankins MR, Ceppa D, Birdas TJ, Vardas PN, Rieger KM.

J Thorac Cardiovasc Surg. 2018 Jun 8. pii: S0022-5223(18)31524-1. doi: 10.1016/j.jtcvs.2018.05.088. [Epub ahead of print]

PMID:
30033105
2.

Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial.

Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges JP, Garrido M, Golan T, Mandala M, Wainberg ZA, Catenacci DV, Ohtsu A, Shitara K, Geva R, Bleeker J, Ko AH, Ku G, Philip P, Enzinger PC, Bang YJ, Levitan D, Wang J, Rosales M, Dalal RP, Yoon HH.

JAMA Oncol. 2018 May 10;4(5):e180013. doi: 10.1001/jamaoncol.2018.0013. Epub 2018 May 10.

3.

Coping Skills Practice and Symptom Change: A Secondary Analysis of a Pilot Telephone Symptom Management Intervention for Lung Cancer Patients and Their Family Caregivers.

Winger JG, Rand KL, Hanna N, Jalal SI, Einhorn LH, Birdas TJ, Ceppa DP, Kesler KA, Champion VL, Mosher CE.

J Pain Symptom Manage. 2018 May;55(5):1341-1349.e4. doi: 10.1016/j.jpainsymman.2018.01.005. Epub 2018 Jan 31.

PMID:
29366911
4.

Blood-based tumor biomarkers in lung cancer for detection and treatment.

Mamdani H, Ahmed S, Armstrong S, Mok T, Jalal SI.

Transl Lung Cancer Res. 2017 Dec;6(6):648-660. doi: 10.21037/tlcr.2017.09.03. Review.

5.

Safety and Antitumor Activity of the Anti-Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma.

Doi T, Piha-Paul SA, Jalal SI, Saraf S, Lunceford J, Koshiji M, Bennouna J.

J Clin Oncol. 2018 Jan 1;36(1):61-67. doi: 10.1200/JCO.2017.74.9846. Epub 2017 Nov 8.

PMID:
29116900
6.

Carboplatin and Etoposide With or Without Palifosfamide in Untreated Extensive-Stage Small-Cell Lung Cancer: A Multicenter, Adaptive, Randomized Phase III Study (MATISSE).

Jalal SI, Lavin P, Lo G, Lebel F, Einhorn L.

J Clin Oncol. 2017 Aug 10;35(23):2619-2623. doi: 10.1200/JCO.2016.71.7454. Epub 2017 Jun 12.

7.

Examining the effect of peer helping in a coping skills intervention: a randomized controlled trial for advanced gastrointestinal cancer patients and their family caregivers.

Mosher CE, Secinti E, Johns SA, O'Neil BH, Helft PR, Shahda S, Jalal SI, Champion VL.

Qual Life Res. 2018 Feb;27(2):515-528. doi: 10.1007/s11136-017-1620-7. Epub 2017 Jun 10.

PMID:
28601957
8.

Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors.

LoRusso PM, Gounder M, Jalal SI, André V, Kambhampati SRP, Loizos N, Hall J, Holzer TR, Nasir A, Cosaert J, Kauh J, Chiorean EG.

Invest New Drugs. 2017 Aug;35(4):442-450. doi: 10.1007/s10637-016-0413-0. Epub 2017 Feb 4.

9.

Separation and dual detection of prostate cancer cells and protein biomarkers using a microchip device.

Huang W, Chang CL, Brault ND, Gur O, Wang Z, Jalal SI, Low PS, Ratliff TL, Pili R, Savran CA.

Lab Chip. 2017 Jan 31;17(3):415-428. doi: 10.1039/c6lc01279e.

PMID:
28054089
10.

Randomized Pilot Trial of a Telephone Symptom Management Intervention for Symptomatic Lung Cancer Patients and Their Family Caregivers.

Mosher CE, Winger JG, Hanna N, Jalal SI, Einhorn LH, Birdas TJ, Ceppa DP, Kesler KA, Schmitt J, Kashy DA, Champion VL.

J Pain Symptom Manage. 2016 Oct;52(4):469-482. doi: 10.1016/j.jpainsymman.2016.04.006. Epub 2016 Jul 9.

11.

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.

Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Yang JC, Gubens M, Sequist LV, Awad MM, Fiore J, Ge Y, Raftopoulos H, Gandhi L; KEYNOTE-021 investigators.

Lancet Oncol. 2016 Nov;17(11):1497-1508. doi: 10.1016/S1470-2045(16)30498-3. Epub 2016 Oct 10.

PMID:
27745820
12.

Small Cell Lung Cancer.

Bernhardt EB, Jalal SI.

Cancer Treat Res. 2016;170:301-22. doi: 10.1007/978-3-319-40389-2_14. Review.

PMID:
27535400
13.

Small-molecule binding sites to explore protein-protein interactions in the cancer proteome.

Xu D, Jalal SI, Sledge GW, Meroueh SO.

Mol Biosyst. 2016 Oct 20;12(10):3067-87. doi: 10.1039/c6mb00231e. Epub 2016 Jul 25.

14.
15.

DNA repair targeted therapy: The past or future of cancer treatment?

Gavande NS, VanderVere-Carozza PS, Hinshaw HD, Jalal SI, Sears CR, Pawelczak KS, Turchi JJ.

Pharmacol Ther. 2016 Apr;160:65-83. doi: 10.1016/j.pharmthera.2016.02.003. Epub 2016 Feb 16. Review.

16.

Novel therapies in small cell lung cancer.

Mamdani H, Induru R, Jalal SI.

Transl Lung Cancer Res. 2015 Oct;4(5):533-44. doi: 10.3978/j.issn.2218-6751.2015.07.20. Review.

17.

Adjuvant Epidermal Growth Factor Receptor Inhibitors in Non-Small Cell Lung Cancer.

Lourdes LS, Jalal SI, Hanna N.

Oncologist. 2015 Sep;20(9):975-8. doi: 10.1634/theoncologist.2015-0182. Epub 2015 Aug 12. No abstract available.

18.

Locally Advanced Non-Small Cell Lung Cancer: Optimal Chemotherapeutic Agents and Duration.

Mamdani H, Jalal SI, Hanna N.

Curr Treat Options Oncol. 2015 Oct;16(10):47. doi: 10.1007/s11864-015-0364-2. Review.

PMID:
26233240
19.

Concurrent Detection of Cellular and Molecular Cancer Markers Using an Immunomagnetic Flow System.

Huang W, Chang CL, Chan BD, Jalal SI, Matei DE, Low PS, Savran CA.

Anal Chem. 2015 Oct 20;87(20):10205-12. doi: 10.1021/acs.analchem.5b02215. Epub 2015 Jul 24.

PMID:
26165381
20.

Circulating tumor cell detection using a parallel flow micro-aperture chip system.

Chang CL, Huang W, Jalal SI, Chan BD, Mahmood A, Shahda S, O'Neil BH, Matei DE, Savran CA.

Lab Chip. 2015 Apr 7;15(7):1677-88. doi: 10.1039/c5lc00100e.

PMID:
25687986
21.

Coping with physical and psychological symptoms: a qualitative study of advanced lung cancer patients and their family caregivers.

Mosher CE, Ott MA, Hanna N, Jalal SI, Champion VL.

Support Care Cancer. 2015 Jul;23(7):2053-60. doi: 10.1007/s00520-014-2566-8. Epub 2014 Dec 20.

22.

Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies: HOG LUN 07-130.

Jalal SI, Hanna N, Zon R, Masters GA, Borghaei H, Koneru K, Badve S, Prasad N, Somaiah N, Wu J, Yu Z, Einhorn L.

Am J Clin Oncol. 2017 Aug;40(4):329-335. doi: 10.1097/COC.0000000000000160.

PMID:
25503432
23.

Treatment of clinical T2N0M0 esophageal cancer.

Hardacker TJ, Ceppa D, Okereke I, Rieger KM, Jalal SI, LeBlanc JK, DeWitt JM, Kesler KA, Birdas TJ.

Ann Surg Oncol. 2014 Nov;21(12):3739-43. doi: 10.1245/s10434-014-3929-6. Epub 2014 Jul 22.

PMID:
25047477
24.

Gastroesophageal junction adenocarcinoma displays abnormalities in homologous recombination and nucleotide excision repair.

Dewalt RI, Kesler KA, Hammoud ZT, Baldridge L, Hattab EM, Jalal SI.

Lung Cancer (Auckl). 2014 Feb 15;5:11-20. doi: 10.2147/LCTT.S57594. eCollection 2014.

25.

Barriers to mental health service use and preferences for addressing emotional concerns among lung cancer patients.

Mosher CE, Winger JG, Hanna N, Jalal SI, Fakiris AJ, Einhorn LH, Birdas TJ, Kesler KA, Champion VL.

Psychooncology. 2014 Jul;23(7):812-9. doi: 10.1002/pon.3488. Epub 2014 Feb 3.

26.

Exploring a structural protein-drug interactome for new therapeutics in lung cancer.

Peng X, Wang F, Li L, Bum-Erdene K, Xu D, Wang B, Sinn AA, Pollok KE, Sandusky GE, Li L, Turchi JJ, Jalal SI, Meroueh SO.

Mol Biosyst. 2014 Mar 4;10(3):581-91. doi: 10.1039/c3mb70503j. Epub 2014 Jan 9.

27.

Support service use and interest in support services among lung cancer patients.

Mosher CE, Hanna N, Jalal SI, Fakiris AJ, Einhorn LH, Birdas TJ, Kesler KA, Champion VL.

Lung Cancer. 2013 Oct;82(1):162-7. doi: 10.1016/j.lungcan.2013.06.020. Epub 2013 Aug 6.

28.

Erlotinib and bevacizumab in newly diagnosed performance status 2 or elderly patients with nonsquamous non-small-cell lung cancer, a phase II study of the Hoosier Oncology Group: LUN04-77.

Riggs H, Jalal SI, Baghdadi TA, Bhatia S, McClean J, Johnson C, Yu M, Taber D, Harb W, Hanna N.

Clin Lung Cancer. 2013 May;14(3):224-9. doi: 10.1016/j.cllc.2012.09.004. Epub 2012 Oct 24.

PMID:
23102811
29.

Economic and social changes among distressed family caregivers of lung cancer patients.

Mosher CE, Champion VL, Azzoli CG, Hanna N, Jalal SI, Fakiris AJ, Birdas TJ, Okereke IC, Kesler KA, Einhorn LH, Monahan PO, Ostroff JS.

Support Care Cancer. 2013 Mar;21(3):819-26. doi: 10.1007/s00520-012-1585-6. Epub 2012 Sep 4.

30.

Support service use and interest in support services among distressed family caregivers of lung cancer patients.

Mosher CE, Champion VL, Hanna N, Jalal SI, Fakiris AJ, Birdas TJ, Okereke IC, Kesler KA, Einhorn LH, Given BA, Monahan PO, Ostroff JS.

Psychooncology. 2013 Jul;22(7):1549-56. doi: 10.1002/pon.3168. Epub 2012 Sep 3.

31.

Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoosier Oncology Group (HOG) and US Oncology.

Jalal SI, Riggs HD, Melnyk A, Richards D, Agarwala A, Neubauer M, Ansari R, Govindan R, Bruetman D, Fisher W, Breen T, Johnson CS, Yu M, Einhorn L, Hanna N.

Ann Oncol. 2012 Jul;23(7):1730-8. doi: 10.1093/annonc/mdr565. Epub 2011 Dec 9.

PMID:
22156624
32.

Novel irreversible small molecule inhibitors of replication protein A display single-agent activity and synergize with cisplatin.

Neher TM, Bodenmiller D, Fitch RW, Jalal SI, Turchi JJ.

Mol Cancer Ther. 2011 Oct;10(10):1796-806. doi: 10.1158/1535-7163.MCT-11-0303. Epub 2011 Aug 16.

33.

The role of maintenance chemotherapy in advanced nonsmall cell lung cancer.

Jalal SI, Ademuyiwa FO, Hanna NH.

Curr Opin Oncol. 2009 Mar;21(2):110-5. doi: 10.1097/CCO.0b013e328322cf49. Review.

PMID:
19532011

Supplemental Content

Loading ...
Support Center